Skip to content
Home/Companies/Pharma/OHRE Pharma

OHRE Pharma

Pharma·France·Exited 2021·Held 3yr
Entry
2018
Hold
3yr
Exit
2021

Who owns OHRE Pharma?

OHRE Pharma is a French Pharma company, now owned by Strategic Generics France, which acquired it in 2021 from VATEL CAPITAL.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
VATEL CAPITAL
Investor
VATEL CAPITAL
Vatel Capital · 2018 · Evergreen

Key facts

HQFrance
SectorPharma
Exit Type
Trade Sale
Buyer
Strategic Generics France
Exit Year
2021

More from Vatel Capital

Other portfolio companies in the same fund.

Agripower
Agripower
Active
EnergyFrance· 2019
Zoomalia
Exited 2025
TMTFrance· 2019
to Holding Nicole
Fill Up Media
Fill Up Media
Active
TMTFrance· 2017

More VATEL CAPITAL portfolio companies

From the same investor, across funds.

Crossject
Active
PharmaFrance· 2025
Enogia
Active
EnergyFrance· 2025
Entech
Entech
Active
ClimateTechFrance· 2025
Haffner Energy
Haffner Energy
Active
ClimateTechFrance· 2025
Hoffmann Green Cement
Hoffmann Green Cement
Active
ClimateTechFrance· 2025
Iznes
Active
FintechFrance· 2025

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns OHRE Pharma?

OHRE Pharma is now owned by Strategic Generics France, which acquired it in 2021 from VATEL CAPITAL.

When did Strategic Generics France acquire OHRE Pharma?

Strategic Generics France acquired OHRE Pharma in 2021, buying from VATEL CAPITAL.

Who did OHRE Pharma sell to?

VATEL CAPITAL sold OHRE Pharma to Strategic Generics France in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue